Digest Network Come funziona
Network
/
Società
AC
Non verificato

ACADIA Pharmaceuticals Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VariePsichiatriaSalute

74 comunicati stampa

Guarda tutti i comunicati
28/04/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
17/04/2026
Eventi
Fiere
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
15/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Psichiatria
Sanità
Salute
Farmaceutica
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
07/04/2026
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
12/03/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
03/03/2026
Mercato del lavoro
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
02/03/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
04/02/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Psichiatria
Salute
Scienza
Farmaceutica
Biotecnologia
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Fonte
ACADIA Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0